Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EryDex in Ataxia Telangiectasia
NCT01255358Phase 2Completed
- Sponsor
- IRulya Therapeutics
- Start
- Feb 2011
- Primary completion
- Sep 2011
- Modality
- Nanoparticles, Small Molecules, Device-based Delivery
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of EryDex in ataxia-telangiectasia (AT), sponsored by IRulya Therapeutics. Primary endpoint: International Cooperative Ataxia Rating Scale at 180 days. Started Feb 2011; status: completed.
02
Drugs
EryDex
03
Conditions
ataxia-telangiectasia (AT)
Beyond the preview
Go deeper on NCT01255358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01255358.